Drugs in ATC Class N07

Up to Top Level ATC Classes

Up to N - Nervous system

Subclasses in ATC: N07 - OTHER NERVOUS SYSTEM DRUGS

N07A - PARASYMPATHOMIMETICS

N07B - DRUGS USED IN ADDICTIVE DISORDERS

N07X - OTHER NERVOUS SYSTEM DRUGS

N07 Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class N07 (Other Nervous System Drugs) reflect a rapidly evolving sector shaped by therapeutic innovation, generic competition, and strategic patent management. Below is a structured analysis based on recent data and trends:

---

Market Dynamics

Growth Projections

• The global CNS therapeutics market, which includes N07 drugs, was valued at $115.4 billion in 2024 and is projected to grow at a 6.7% CAGR to reach $235.5 billion by 2035[14]. Specific subcategories like anti-psychotics and Parkinson’s disease therapies are key growth drivers.
• N07 drugs accounted for 3.3% of Belgium/Luxembourg’s retail pharmaceutical market by value in 2019, highlighting regional variability in adoption[7].

Generic Penetration

• Generic competition significantly impacts N07:
  • Over 75% of molecules in therapeutic classes like N07 faced generic competition in the UK after patent expiry[1].
  • Markets with higher generic shares correlate with larger molecule market sizes (e.g., statins, analgesics)[6]. For N07, growth in generic expenditure was noted in high-value markets[6].

Key Therapeutic Areas

• Parkinson’s disease therapies (e.g., levodopa, pimavanserin) dominate the N07 landscape. Despite generics for older drugs like levodopa, novel agents such as AbbVie’s Nuplazid (pimavanserin) face upcoming patent expiries (May 2025)[4].
• Multiple sclerosis (MS) therapies, though categorized under broader CNS classes, influence adjacent markets. Biogen’s Tecfidera (dimethyl fumarate), set to lose exclusivity in March 2025, will intensify price competition[3][4].

---

Patent Landscape

Upcoming Patent Cliffs

• 25 high-revenue drugs lose protection in 2025, including:
  • Vraylar (cariprazine) (AbbVie, May 2025): Used for schizophrenia and bipolar disorder[4].
  • Entresto (sacubitril/valsartan) (Novartis, July 2025): Litigation tactics delayed generics, but FDA approvals for copycats signal market disruption[10].
• Specialized therapies like safinamide (Parkinson’s) and Nuplazid are transitioning to generics, reducing originator revenues by 30–70%[9].

Strategic Responses

• Originator Strategies:
  • Legal delays: Novartis filed petitions to block Entresto generics, though FDA denied the request[10].
  • Pipeline diversification: Companies like Johnson & Johnson invest in novel biologics and gene therapies to offset losses[12][14].
• Regulatory Pathways: FDA’s Competitive Generic Therapy (CGT) designation incentivizes generics in underserved markets, though patent thickets remain barriers[11].

---

Competitive Forces

Market Leaders

• Dominant players include Biogen, Johnson & Johnson, Roche, and Novartis, which focus on neurology pipelines[12][13].
• Teva, Viatris, and Sun Pharma lead in generics, leveraging economies of scale[12].

Pricing Pressures

• Predatory pricing risks emerge as generics enter. EU regulations prohibit below-cost pricing (e.g., AKZO case rules)[5].
• Generic entry reduces branded drug prices by 50–90%, as seen in statins and anti-psychotics[1][6].

---

Emerging Trends

Innovation Drivers

• Biologics and gene therapies: Companies prioritize CNS drugs with novel mechanisms (e.g., Roche’s Ocrevus for MS)[3][14].
• Digital therapeutics: Adjacent technologies complement pharmacotherapy for disorders like Parkinson’s[9].

Market Entry Barriers

• Complex manufacturing: Drugs requiring specialized formulations (e.g., extended-release) deter generics[1].
• Regulatory hurdles: Fast-track approvals reduce generic interest, as seen in CGT-designated drugs[11].

---

Future Outlook

• 2025–2030 will see accelerated generic substitution for N07 drugs like pimavanserin and cariprazine.
• Revenue recovery for originators will depend on next-gen therapies (e.g., biologics) and strategic lifecycle management[10][14].

Key Insight: The N07 market balances innovation with cost containment, driven by aging populations and CNS disorder prevalence. Generic dominance is inevitable for small-molecule drugs, but biologic therapies offer sustained revenue streams[3][14].

---

Key Takeaways

1. Growth: CNS market to double by 2035, led by N07 agents for Parkinson’s and schizophrenia.
2. Generics: Patent expiries (2025–2026) will reduce branded drug revenues by $10B+ annually.
3. Innovation: Biologics and digital tools offset generic pressures but require heavy R&D investment.

FAQs

1. Which N07 drugs face imminent patent expiry?
   Vraylar (2025), Tecfidera (2025), and Nuplazid (2025) are key examples[4][9].

2. How do generics impact N07 pricing?
   Generics reduce prices by 50–90%, increasing access but squeezing margins[1][6].

3. What strategies do originators use to delay generics?
   Patent litigation, FDA petitions, and lifecycle management (e.g., new formulations)[10].

4. Are biologics replacing small-molecule N07 drugs?
   Partially; biologics target niche populations, while generics dominate mass markets[3][14].

5. Which regions lead in N07 adoption?
   Europe and North America drive growth, but Asia-Pacific shows rising demand due to aging demographics[13][14].

References

1. https://openaccess.city.ac.uk/25481/10/Serra-Sastre2020_Article_DoesNICEInfluenceTheAdoptionAn.pdf
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10128997/
3. https://www.ihealthcareanalyst.com/global-central-nervous-system-therapeutics-market/
4. https://biopharmaapac.com/analysis/60/5727/25-high-value-drugs-losing-patent-protection-in-2025-what-it-means-for-healthcare.html
5. https://www.concurrences.com/en/dictionary/predatory-pricing
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8841453/
7. https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2019/belgian-reg-med-best-performers-for-july-2019.pdf?la=en&hash=EC30C5B2F4035D704D9E4BCA873B4E04
8. https://www.frontiersin.org/articles/10.3389/frma.2023.978249/full
9. https://www.maxval.com/blog/pharma-patent-landscape-parkinsons-disease-uncovered/
10. https://www.biospace.com/business/5-pharma-powerhouses-facing-massive-patent-cliffs-and-what-theyre-doing-about-it
11. https://journals.plos.org/plosmedicine/article/file?id=10.1371%2Fjournal.pmed.1004540&type=printable
12. https://www.alliedmarketresearch.com/central-nervous-system-cns-therapeutics-market-A305147
13. https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market
14. https://www.metatechinsights.com/industry-insights/central-nervous-system-therapeutics-market-1563